The company sold 1,970,000 shares at $1.68 per share and pre-funded warrants for up to 1,601,429 shares to one investor, and issued Series A and Series B warrants in a concurrent private placement.
Latest NanoViricides news
We have not published a story on NanoViricides yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-K): cash and equivalents $2.8 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about NanoViricides
Has NanoViricides raised money recently?
Our latest story on this, dated Nov 14, 2025: "NanoViricides closes registered direct offering with gross proceeds of about $6.0 million". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of NanoViricides?
NanoViricides, Inc. trades under the ticker NNVC on AMEX.
Where is NanoViricides listed?
NanoViricides, Inc. is listed on AMEX. Our directory also records these other listings: GETTEX:NV3P.
What is the SEC CIK of NanoViricides?
The SEC Central Index Key (CIK) for NanoViricides, Inc. is 1379006. Its filings are on SEC EDGAR.
How many shares does NanoViricides have outstanding?
25,525,000 shares as of 2026-09-28, per the cover page of its 10-K filed 2026-09-28.
Which country or territory is NanoViricides listed under?
Our directory records NanoViricides, Inc. under United States.
What does NanoViricides do?
Our directory classifies NanoViricides, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of NanoViricides?
The ISIN recorded for NanoViricides, Inc. is US6300873022.
Does aibio.space cover NanoViricides?
aibio.space lists NanoViricides, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is NanoViricides incorporated?
SEC records list its state or country of incorporation as DE.
Is NanoViricides profitable?
NanoViricides, Inc. reported a net loss of $8.2 million for the fiscal year ended Jun 30, 2026, and used $7.7 million of cash in operations, per its annual report to the SEC.
How much does NanoViricides spend on research and development?
$4.7 million in the fiscal year ended Jun 30, 2026, per its annual report.
How much cash does NanoViricides have?
$2.8 million in cash at Jun 30, 2026, per its 10-K.
What is the latest NanoViricides (NNVC) stock news?
Our latest story on NanoViricides, dated Nov 14, 2025: "NanoViricides closes registered direct offering with gross proceeds of about $6.0 million". The company sold 1,970,000 shares at $1.68 per share and pre-funded warrants for up to 1,601,429 shares to one investor, and issued Series A and Series B warrants in a concurrent private placement. Source.
What is NanoViricides's market cap?
We do not publish live share prices. In its annual report, NanoViricides, Inc. put the market value of shares held by non-affiliates (public float) at $23.7 million as of Dec 31, 2025.
Investor discussion: NanoViricides
Members talk about NanoViricides (NNVC). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at NanoViricides, newest first. Each line links the filing it comes from.
Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open AMEX:NNVC on TradingView.
SEC filings and registration
SEC name
Nanoviricides, Inc.
CIK
1379006
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
NNVC (NYSE)
State or country of incorporation
DE
Fiscal year ends
June 30
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
1 CONTROLS DRIVE, SHELTON, CT, 06484
Phone
(203) 668-5580
Shares outstanding
25,525,000 as of 2026-09-28 (10-K filed 2026-09-28)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
NanoViricides, Inc. is a public biotech or pharmaceutical company listed on AMEX under the ticker NNVC, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio